by Randy Miller | Oct 22, 2026 | FDA, FOIA
FOIAengine: Fresenius Companies Targeted in 65 FOIA Requests Fresenius SE & Co. KGaA (FRE GR), the German healthcare group, and its affiliates were targeted by a major wave of Freedom of Information Act requests to the Food and Drug Administration in the first...
by Randy Miller | Sep 24, 2026 | FDA, FOIA, Hedge Funds
FOIAengine: Sofinnova Bet on Drug FDA Approved Last Week Shares of Ultragenyx Pharmaceutical Inc. rose 16 percent September 17 after the Food and Drug Administration approved Fayuvi, its gene therapy for Sanfilippo syndrome Type A, a rare and devastating genetic...
by John A. Jenkins | Sep 3, 2026 | FDA, FOIA
FOIAengine: Newly Remade Advisory Committee Green Lights Six Compounds, Despite the Applications Being Pulled Bobby Harshbarger is a Tennessee state senator and pharmacist of noteworthy lineage, with an interesting backstory. Both of his parents are...
by Randy Miller | Aug 20, 2026 | FDA, FOIA, News Media, Politics
FOIAengine: Twenty-One Requests from News Media, Non-Profits and Companies The nationwide outbreak of cyclospora infections this summer prompted a steady stream of national and local news articles, along with 21 Freedom of Information Act requests to the Food and Drug...
by John A. Jenkins | Aug 5, 2026 | FDA, FOIA, Hedge Funds, Pharmaceuticals, Stock Market
FOIAengine: Requests from Point72, Sofinnova, Holocene, Triple Gate and Others A review of the latest Freedom of Information Act requests targeting three life-sciences companies – Novo Nordisk (NYSE: NVO); Charles River Laboratories (NYSE: CRL); and iRhythm...
by John A. Jenkins | Jul 30, 2026 | FDA, FOIA, News Media, Pharmaceuticals, Politics
FOIAengine: Multiple News Outlets Sought Details on “Compassionate Use” Within days of a Stat News report describing a highly unusual government decision to grant a 79-year-old patient early access to Eli Lilly’s experimental obesity drug retatrutide, some of the...
